104 related articles for article (PubMed ID: 35489191)
1. Genetic predisposition to papillary thyroid carcinoma is mediated by a long non-coding RNA TINCR enhancer polymorphism.
Wang Q; Huang H; Chen P; Xiao X; Luo X; Wang Y; Long S; Gao L; Zhang L
Int Immunopharmacol; 2022 Aug; 109():108796. PubMed ID: 35489191
[TBL] [Abstract][Full Text] [Related]
2. Expression of
Icduygu FM; Akgun E; Sengul D; Ozgoz A; Alp E
Mol Med Rep; 2022 Apr; 25(4):. PubMed ID: 35147200
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA POLR2E rs3787016 is associated with the risk of papillary thyroid carcinoma in Chinese population.
Chen B; Li J; Yi C; Jiao Y; Gu X; Feng X
Pathol Res Pract; 2018 Jul; 214(7):1040-1044. PubMed ID: 29724531
[TBL] [Abstract][Full Text] [Related]
4. Multiple functional variants in long-range enhancer elements contribute to the risk of SNP rs965513 in thyroid cancer.
He H; Li W; Liyanarachchi S; Srinivas M; Wang Y; Akagi K; Wang Y; Wu D; Wang Q; Jin V; Symer DE; Shen R; Phay J; Nagy R; de la Chapelle A
Proc Natl Acad Sci U S A; 2015 May; 112(19):6128-33. PubMed ID: 25918370
[TBL] [Abstract][Full Text] [Related]
5. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type.
Jendrzejewski J; He H; Radomska HS; Li W; Tomsic J; Liyanarachchi S; Davuluri RV; Nagy R; de la Chapelle A
Proc Natl Acad Sci U S A; 2012 May; 109(22):8646-51. PubMed ID: 22586128
[TBL] [Abstract][Full Text] [Related]
6. Risk genetic polymorphism and haplotype associated with papillary thyroid cancer and their relation to associated diseases in Slovak population.
Duffek M; Skerenova M; Halasova E; Sarlinova M; Dzian A; Repiska V; Dobrovodsky A; Mistuna D; Bernadic M; Matakova T
Bratisl Lek Listy; 2022; 123(7):475-48. PubMed ID: 35907052
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma.
Bingül İ; Vural P; Doğru-Abbasoğlu S; Çil E; Uysal M
J Clin Lab Anal; 2017 Nov; 31(6):. PubMed ID: 27925342
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the function of EPB41L4A in the predisposition to papillary thyroid carcinoma.
Comiskey DF; He H; Liyanarachchi S; Sheikh MS; Hendrickson IV; Yu L; Brock PL; de la Chapelle A
Sci Rep; 2020 Nov; 10(1):19984. PubMed ID: 33203992
[TBL] [Abstract][Full Text] [Related]
9. Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.
He H; Li W; Liyanarachchi S; Jendrzejewski J; Srinivas M; Davuluri RV; Nagy R; de la Chapelle A
J Clin Endocrinol Metab; 2015 Jan; 100(1):E164-72. PubMed ID: 25303483
[TBL] [Abstract][Full Text] [Related]
10. The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.
He H; Li W; Liyanarachchi S; Wang Y; Yu L; Genutis LK; Maharry S; Phay JE; Shen R; Brock P; de la Chapelle A
J Clin Endocrinol Metab; 2018 Apr; 103(4):1369-1379. PubMed ID: 29121253
[TBL] [Abstract][Full Text] [Related]
11. Genotype Analyses in the Japanese and Belarusian Populations Reveal Independent Effects of rs965513 and rs1867277 but Do Not Support the Role of FOXE1 Polyalanine Tract Length in Conferring Risk for Papillary Thyroid Carcinoma.
Nikitski AV; Rogounovitch TI; Bychkov A; Takahashi M; Yoshiura KI; Mitsutake N; Kawaguchi T; Matsuse M; Drozd VM; Demidchik Y; Nishihara E; Hirokawa M; Miyauchi A; Rubanovich AV; Matsuda F; Yamashita S; Saenko VA
Thyroid; 2017 Feb; 27(2):224-235. PubMed ID: 27824288
[TBL] [Abstract][Full Text] [Related]
12. MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression.
Roncevic J; Djoric I; Selemetjev S; Jankovic J; Dencic TI; Bozic V; Cvejic D
Pathology; 2019 Jan; 51(1):55-61. PubMed ID: 30497805
[TBL] [Abstract][Full Text] [Related]
13. The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma.
Li W; Wang T; Fu G; Xu Y; Zhang N; Han L; Yang M
Endocr Relat Cancer; 2023 Jan; 30(1):. PubMed ID: 36305508
[TBL] [Abstract][Full Text] [Related]
14. Onco-lncRNA HOTAIR and its functional genetic variants in papillary thyroid carcinoma.
Zhu H; Lv Z; An C; Shi M; Pan W; Zhou L; Yang W; Yang M
Sci Rep; 2016 Aug; 6():31969. PubMed ID: 27549736
[TBL] [Abstract][Full Text] [Related]
15. SP1-induced upregulation of long noncoding RNA LINC00313 contributes to papillary thyroid cancer progression via the miR-422a.
Yan DG; Liu N; Chao M; Tu YY; Liu WS
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1134-1144. PubMed ID: 30779082
[TBL] [Abstract][Full Text] [Related]
16. Association between IL-27 gene polymorphisms and risk of papillary thyroid carcinoma.
Nie X; Yuan F; Chen P; Pu Y; Zhu J; Wang Y; Xiao X; Che G; Gao L; Zhang L
Biomark Med; 2017 Feb; 11(2):141-149. PubMed ID: 27929666
[TBL] [Abstract][Full Text] [Related]
17. lncRNA GAS8-AS1 genetic alterations in papillary thyroid carcinoma and their clinical significance.
Zhou DL; Liu Q; Xu BH; Li Y; Su X; Ye ZL; Zhang X; Peng JL; Deng L; Tang T; Shao Q; Ma JJ; Yang XH; He CY
Cancer Biomark; 2020; 29(2):255-264. PubMed ID: 32675393
[TBL] [Abstract][Full Text] [Related]
18. Association between single nucleotide polymorphisms of upstream transcription factor 1 (USF1) and susceptibility to papillary thyroid cancer.
Yuan Q; Bu Q; Li G; Zhang J; Cui T; Zhu R; Mu D
Clin Endocrinol (Oxf); 2016 Apr; 84(4):564-70. PubMed ID: 26052935
[TBL] [Abstract][Full Text] [Related]
19. Associations between promoter polymorphism -106A/G of interleukin-11 receptor alpha and papillary thyroid cancer in Korean population.
Eun YG; Shin IH; Kim MJ; Chung JH; Song JY; Kwon KH
Surgery; 2012 Feb; 151(2):323-9. PubMed ID: 21982075
[TBL] [Abstract][Full Text] [Related]
20. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.
Meng XF; Zhao LY; Chu XF
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
